TPST vs. ADCT, XOMA, MRSN, ENTA, FHTX, EPIX, QURE, AQST, NKTR, and ELYM
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include ADC Therapeutics (ADCT), XOMA (XOMA), Mersana Therapeutics (MRSN), Enanta Pharmaceuticals (ENTA), Foghorn Therapeutics (FHTX), ESSA Pharma (EPIX), uniQure (QURE), Aquestive Therapeutics (AQST), Nektar Therapeutics (NKTR), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical preparations" industry.
ADC Therapeutics (NYSE:ADCT) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
ADC Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.78, meaning that its share price is 278% less volatile than the S&P 500.
In the previous week, ADC Therapeutics had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 0.49 beat ADC Therapeutics' score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the media.
41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 4.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 3.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Tempest Therapeutics has a net margin of 0.00% compared to Tempest Therapeutics' net margin of -330.17%. ADC Therapeutics' return on equity of -232.39% beat Tempest Therapeutics' return on equity.
Tempest Therapeutics received 41 more outperform votes than ADC Therapeutics when rated by MarketBeat users. However, 65.00% of users gave ADC Therapeutics an outperform vote while only 64.14% of users gave Tempest Therapeutics an outperform vote.
ADC Therapeutics currently has a consensus price target of $7.25, indicating a potential upside of 111.99%. Tempest Therapeutics has a consensus price target of $25.00, indicating a potential upside of 703.86%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than ADC Therapeutics.
Tempest Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
ADC Therapeutics beats Tempest Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
